ThinkEquity Initiates Coverage on Gen-Probe (GPRO) with a Buy
More News related to GPRO
- Xenomics, Inc. and Its Subsidiary TrovaGene, Inc. Announce HPV Patent Filing Based on Transrenal DNA Technology
- Gen-Probe to Webcast Two Upcoming Investor Presentations
- Gen-Probe (GPRO) Tops Q3 EPS by 6c; Narrows Guidance
- Gen-Probe Reports Financial Results for Third Quarter 2009
- Gen-Probe (GPRO) Gets Emergency Use Authorizaton From U.S. FDA for Prodesse ProFlu-ST Test
More News related to New Coverage
- FBR Capital Downgrades Pike Electric (PIKE) to Market Perform; Awaiting Improved Visibility
- Deutsche Bank Downgrades TRW Automotive (TRW) to Hold; Valuation Call
- Piper Jaffray Downgrades GT Solar International (SOLR) to Underweight
- XOMA (XOMA) Falls Modestly Following After-Hours Downgrade
- Morgan Stanley Upgrades CHU to Overweight, Downgrades CHL, CHA to Equal Weight
ThinkEquity initiates coverage on Gen-Probe (Nasdaq: GPRO) with a Buy rating. Price target $55.
To see more analyst ratings on GRPO Click Here.
Gen-Probe Incorporated (Gen-Probe) is engaged in the development, manufacture and marketing of nucleic acid probe-based products used for the clinical diagnosis of human diseases and for screening donated human blood.
Related Categories
New CoverageStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
